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BACKGROUND:  Patients with metastatic adenocarcinoma of unknown origin
are a common clinical problem.  Knowledge of the primary site is important for
their management, but histologically such tumours appear similar.  Better
diagnostic markers are needed to enable the assignment of metastases to likely
sites of origin on pathological samples.
METHODS:  Expression profiling of 27 candidate markers was performed
using tissue microarrays and immunohistochemistry.  In the first round, we
studied 352 primary adenocarcinomas, from seven main sites (breast, colon,
lung, ovary, pancreas, prostate and stomach) and their differential diagnoses.
Data were analysed in Microsoft® Access and the Rosetta system and used to
develop a classification scheme.  In the second round, we studied 100 primary
adenocarcinomas and 30 paired metastases.
RESULTS:  In the first round, we generated expression profiles for all 27
candidate markers in each of the seven main primary sites.  Data analysis led to
a simplified diagnostic panel and decision tree containing 10 markers only:
CA125, CDX2, CK7, CK20, ER, GCDFP-15, lysozyme, mesothelin, PSA and
TTF1.  Applying the panel and tree to the original data provided correct
classification in 88%.  The 10 markers and diagnostic algorithm were then
tested in a second, independent, set of primary and metastatic tumours and
again 88% were correctly classified.
CONCLUSIONS:  This classification scheme should enable better prediction
on biopsy material of the primary site in patients with metastatic
adenocarcinoma of unknown origin, leading to improved management and
therapy.
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Myofibroblasts Associated with Liver Tumours are
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Aim: Myofibroblasts produce the tumour capsule seen around certain liver
cancers and may have a pro-angiogenic role in liver metastasis. We have
recently found that a significant proportion of hepatic myofibroblasts are of
bone marrow (BM) origin in human liver fibrosis. Our aim was to identify
whether myofibroblasts associated with liver tumours had a BM origin in a
murine model of chronic liver injury and hepatocellular carcinoma.
Methods: Hepatitis B surface antigen transgenic female mice (HBsAg-tg)
received lethal irradiation followed by a BM transplant with whole or lineage-
depleted (Lin
-) BM from a wild-type male donor. Prior to transplantation the
BM cells were transduced with a HIV vector carrying the GFP marker gene
under the control of a spleen focus forming virus (SFFV) promoter. After 6
weeks mice were treated with retrorsine to block hepatocyte regeneration. After
this, half of them received splenocytes from females immunized with HBsAg
DNA plasmid. After 6 months the animals were sacrificed and BM derived
cells were tracked using in-situ hybridisation (ISH) for the Y chromosome and
immunohistochemistry for GFP.
Results: Tumours were seen within the livers. The hepatocytes within the liver
cancers were not BM derived. There were numerous Y chromosome positive
myofibroblasts. Smooth muscle cells within large vessel walls were frequently
of BM origin.
Conclusions: Many myofibroblasts associated with liver tumours are of BM
origin in this model. Both the whole and Lin
- fraction of BM contains cells with
a myofibroblast potential. These circulating cells may have a role in the
pathogenesis of liver tumour development.
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Dystroglycan is a protein with extracellular α and transmembrane β subunits
which link the extracellular matrix and cytoskeleton by binding to laminin and
other matrix molecules. Previously published studies have shown reduced
expression of α-dystroglycan in many cancers but β-dystroglycan has only been
investigated in a few cases of prostate, breast and oral cancer. We have
performed an immunohistochemical survey of β-dystroglycan expression on
custom made tissue arrays containing 389 tissue cores representing 29 human
tissue types and 23 different tumour types. Immunohistochemistry for
dystroglycan was performed using a monoclonal antibody raised against the
cytoplasmic domain of β-dystroglycan. In normal glandular and transitional
epithelium there was strong dystroglycan expression at the intercellular junction
between the epithelial cells, and between epithelial cells and the basement
membrane. In squamous epithelium there was strong intercellular staining in
the basal epithelial layers in skin and cervix but this was absent in the
oesophagus. β-dystroglycan was completely absent or very weakly expressed in
the majority of cancers including 98% of colorectal cancers (81 cases), 100% of
ureteric transitional cell cancers (57 cases), 100% of oesophageal cancers (10
squamous, 10 adenocarcinoma) but it was present in some malignant tumours
including cutaneous basal cell cancers. This is the first comprehensive survey of
β-dystroglycan expression in human tissues and cancers. The absence of this
important transmembrane protein in the majority of cancers may play a
significant role in tumour progression and the mechanisms for this require
further investigation.
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Introduction. Bone marrow (BM) cells engraft in non-haematopoietic tissues
and form adult cell lineages. We investigated the contribution of BM to
epidermal regeneration. Method. Lethally-irradiated female mice were rescued
by BM transplant from GFP
 male mice. Epidermal wounding was induced 6
weeks post-transplant. Epidermis was harvested 4, 7 and 30 days post-
wounding, or keratinocytes were isolated from the epidermis and re-suspended
in growth medium. BrDU was injected 2 hours before sacrifice. Donor cells
were detected by GFP immunohistochemistry (IHC), or in situ hybridisation
(ISH) for Y chromosome, combined with IHC. For fusion studies, a similar
model was employed using male wild type (WT) recipients. Results. BM
contributes to 7.2% of keratinocytes in normal epidermis, increasing
significantly to 11.5% in wounded epidermis. BMDKs were present in clusters
in the regenerating epidermis. BMDKs frequently engrafted epidermal stem cell
zones and often expressed CD34, an epidermal stem cell marker. In the
epidermis, BM-derived cells, morphologically typical of keratinocytes, were
negative for macrophage marker F4/80, and neutrophil marker, Ly6G.
Fluorescent IHC for GFP, keratin-14 (k14), and BrDU showed that BMDKs
proliferate: supported by the presence of GFP+, k14+ keratinocyte in vitro
colonies from WT epidermis transplanted with GFP+ BM. ISH for Y
chromosome combined with GFP and k14 IHC in epidermis from male WT
mice transplanted with male GFP+ BM, showed that GFP+ cells express k14,
but do not fuse with pre-existing keratinocytes. Conclusion. We demonstrate for
the first time, BMDKs capable of proliferation in vivo, without fusion with
native keratinocytes.
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